Brainsway announces BCBS of LA has reduced requirements for TMS treatment

BrainsWay announced that Blue Cross Blue Shield of Louisiana, BCBS of LA, has joined the growing list of payors reducing the patient eligibility requirements for transcranial magnetic stimulation, TMS, treatment from four failed medication trials to two. “We applaud BCBS of LA’s dedication to advancing mental health coverage and facilitating improved outcomes for individuals grappling with mental health conditions,” said Hadar Levy, Chief Executive Officer of BrainsWay. “Treatment-resistant depression patients often spend years of treatment and trials with limited relief, and this policy update will effectively reduce the barriers for these patients in gaining earlier access to our lifechanging technology.”